# Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer

> **NCT05162118** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 51 (estimated)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab

## Key facts

- **NCT ID:** NCT05162118
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-08
- **Primary completion:** 2025-03-22
- **Final completion:** 2025-12-22
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2022-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162118, "Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05162118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*